Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to the extraordinary general meeting to be held on 5 December 2025 at 09.00 CET at Advokatfirman Schjødt, Hamngatan 27, in Stockholm. The registration to the meeting will open at 08.30 CET.
This notice is a translation of a Swedish notice and in case of any deviations between the language versions, the Swedish version shall prevail.
Right to participate and notice of participation
A shareholder who wishes to participate at the general meeting must:
| (i) | be recorded in the share register maintained by Euroclear Sweden AB on 27 November 2025, and |
| (ii) | notify the Company of its intention to participate by post to Advokatfirman Schjødt, attn: Victor Marklund, Box 715, 101 33 Stockholm, or by e-mail to victor.marklund@schjodt.com, no later than on 1 December 2025. The notification shall include full name, personal identification number or corporate registration number, address, telephone number, shareholding and, if applicable, information about assistants (not more than two). |
Nominee-registered shares
Shareholders whose shares are held in the name of a nominee must, in order to be able to participate at the extraordinary general meeting and exercise their voting right, temporarily re-register the shares in their own name in the share register maintained by Euroclear Sweden AB (so-called voting right registration). When preparing the share register for the general meeting as of the record date, 27 November 2025, voting right registrations completed by the nominee no later than on 1 December 2025 will be considered. This means that the shareholders must request that the nominee completes such voting right registration well in advance of 1 December 2025.
Participation by proxy
Shareholders represented by proxy must issue a power of attorney for the proxy. If the power of attorney is issued by a legal entity, a copy of the legal entity's certificate of registration, showing who has authority to issue the power of attorney, must be enclosed. The original version of the power of attorney and, if applicable, the certificate of registration, should well in advance of the general meeting, be sent by post to Advokatfirman Schjødt, attn: Victor Marklund, Box 715, 101 33 Stockholm, or by e-mail to victor.marklund@schjodt.com. The power of attorney must not be older than one year unless a longer validity term (however not longer than five years) is specifically stated in the power of attorney. A proxy form is available on the Company's website, www.scibase.com.
Proposed agenda
- Opening of the meeting.
- Election of chairman of the meeting.
- Preparation and approval of the voting list.
- Approval of the agenda.
- Election of one person who shall approve the minutes of the meeting.
- Determination of whether the meeting has been duly convened.
- Resolution to authorise the board of directors to resolve on issuances of shares.
- Closing of the meeting.
THE BOARD OF DIRECTORS' PROPOSED RESOLUTIONS
Item 7 - Resolution to authorise the board of directors to resolve on issuances of shares
The board of directors proposes that the extraordinary general meeting authorises the board of directors to, until the next annual general meeting, on one or more occasions, with deviation from the shareholders' preferential rights, decide upon issuances of shares in the Company. Subscribed shares shall be paid in cash, by way of set-off or with contribution in kind, or otherwise be conditional. The reason for the deviation shall be to enable payment with own shares in connection with buyback of issued warrants of series TO2.
The chairman of the board of directors, the CEO or a person appointed by the board of directors shall be authorised to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office.
Majority requirements
A resolution in accordance with the proposal, item 7, is valid only when supported by shareholders holding not less than two thirds of both the votes cast and of the shares represented at the general meeting.
Documentation etc.
Related documentation will be available at the Company's office and on the Company's website, www.scibase.com, no later than two weeks prior to the general meeting and will be sent free of charge to shareholders who so request and provide their postal address.
This notice is a translation of a Swedish notice and in case of any deviations between the language versions, the Swedish version shall prevail.
Shareholders' right to request information
Shareholders are reminded of their right to request information from the board of directors and managing director in accordance with Chapter 7 Section 32 of the Swedish Companies Act.
Use of personal data
For information regarding the processing of your personal data, please see the integrity policy that is available at Euroclear Sweden AB's website: www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.
_________________
Stockholm in November 2025
SciBase Holding AB (publ)
The board of directors
For further information please contact:
Pia Renaudin, CEO,
Phone. +46732069802
E-mail: pia.renaudin@scibase.com
Certified Advisor (CA):
DNB Carnegie Investment Bank AB (publ)
Tel: +46 8 588 68 570
E-mail: certifiedadviser@carnegie.se
About SciBase and Nevisense
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases